FGFR1 and pancreatic neuroendocrine tumor: Surufatinib (Sulanda® in China) is an oral, small-molecule, anti-VEGFR kinase inhibitor that targets VEGFR-1, -2, and -3, FGFR-1, and colony-stimulating factor-1 receptor (CSF-1R) (15) and was approved in China for the treatment of pancreatic and non-pancreatic neuroendocrine tumors (16).